Standout Papers
- Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer (2023)
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study (2023)
Immediate Impact
2 by Nobel laureates 3 from Science/Nature 56 standout
Citing Papers
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
2024 Standout
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
2024 Standout
Works of Michael Method being referenced
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Standout
Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Michael Method | 454 | 618 | 192 | 286 | 68 | 1.2k | |
| Margaret Davy | 463 | 426 | 115 | 380 | 53 | 1.4k | |
| Salvatore Lopez | 604 | 528 | 209 | 589 | 88 | 1.5k | |
| Paola Todeschini | 242 | 403 | 185 | 212 | 65 | 1.2k | |
| Vanda Salutari | 694 | 531 | 165 | 386 | 101 | 1.4k | |
| Anneke M. Westermann | 337 | 413 | 302 | 310 | 73 | 1.4k | |
| Edward Podczaski | 483 | 426 | 150 | 469 | 63 | 1.2k | |
| Francesco Spina | 248 | 425 | 93 | 279 | 53 | 1.2k | |
| Maria Del Pilar Estevez-Diz | 266 | 511 | 137 | 233 | 77 | 1.2k | |
| Hugh R. K. Barber | 414 | 343 | 101 | 366 | 80 | 1.2k | |
| Kohei Nakamura | 272 | 390 | 236 | 226 | 108 | 1.0k |
All Works
Loading papers...